{
    "nct_id": "NCT05370521",
    "official_title": "A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens",
    "inclusion_criteria": "* Female subjects aged 18 to 40 years old at Screening visit\n* Diagnosis of PCOS (either historical or during Screening) according to NIH (1990) criteria\n* DHEAS level > age-matched upper limit of normal (ULN) at Screening visit\n* Agree to follow industry standard contraception guidelines within protocol\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 40 Years",
    "exclusion_criteria": "* Evidence of:\n\n  1. History of congenital adrenal hyperplasia (CAH), Cushing's syndrome, pituitary or adrenal disease\n  2. Clinically significant hyperprolactinemia\n  3. Thyroid stimulating hormone (TSH) <0.1 mU/mL or >4.5mU/mL at Screening\n  4. Cortisol levels concerning for adrenal insufficiency\n  5. Other findings suggestive of secondary cause for anovulation and/or hyperandrogenemia\n* Total testosterone levels >140 ng/dL, DHEAS >650 mcg/dL, virilization or other signs or symptoms concerning for ovarian hyperthecosis or androgen-secreting tumors\n* Medical conditions that require glucocorticoid treatment within 30 days of screening and throughout the duration of the study\n* Clinically significant unstable medical conditions, illness, or chronic diseases\n* Prior hysterectomy or bilateral oophorectomy\n* Females who are pregnant or nursing",
    "miscellaneous_criteria": ""
}